Despite enormous advances being made in diagnosis and therapeutic interventions, pancreatic ductal adenocarcinoma (PDAC) is still recognized as one of the most lethal malignancies. Early diagnosis and timely curative surgery can markedly improve the prognosis; hence, there is an unmet necessity to explore efficient biomarkers for patients’ benefit. Recently, blood miRNAs (miRNAs) have been reported to be a novel biomarker in human cancers. Part of it is selectively packaged by plasma exosomes released from cells via exocytosis and is highly sensitive to changes in the tumor microenvironment. Furthermore, due to less invasiveness and technical availability, miRNA-based liquid biopsy holds promise for further wide usage. Therefore, this review is aimed at presenting an update on the association between blood miRNAs and the biology of PDAC, then discussing its clinical utilization further.

中文翻译：

---

胰导管腺癌中血液MicroRNA的技术发展水平。

尽管在诊断和治疗干预方面取得了巨大进展，但胰管腺癌（PDAC）仍被认为是最致命的恶性肿瘤之一。早期诊断和及时进行根治性手术可明显改善预后；因此，有必要探索有效的生物标记物以使患者受益。最近，血液miRNA（miRNA）被报道是人类癌症中的一种新型生物标记。它的一部分被通过胞吐作用从细胞释放的血浆外泌体选择性地包装，并且对肿瘤微环境的变化高度敏感。此外，由于具有较低的侵入性和技术可用性，基于miRNA的液体活检具有广阔的应用前景。因此，本综述旨在提供有关血液miRNA与PDAC生物学之间的关联的最新信息，